Reproducibility of the kinetic analysis of 3′-deoxy-3′-[18F]fluorothymidine positron emission tomography in mouse tumor models

Nuclear Medicine and Biology

Volumn 36, Issue 7, 2009, Pages 711-719

  Choi, Seung Jin ^a   Kim, Seog Young ^a   Kim, Su Jin ^b   Lee, Jae Sung ^b   Lee, Sang Ju ^c   Park, Soo Ah ^d   Lee, Seung Jin ^d   Yun, Sung Cheol ^a   Im, Ki Chun ^a   Oh, Seung Jun ^a,d   Kim, Sang We ^d   Kim, Jae Seung ^a,d   Ryu, Jin Sook ^a,d   Moon, Dae Hyuk ^a,d  

^a University of Ulsan College of Medicine   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Sogang University   (South Korea)

^d Asan Medical Center   (South Korea)

Author keywords

3 Deoxy 3 18F fluorothymidine; Kinetic analysis; Mouse; Positron emission tomography; Reproducibility

Indexed keywords

3' FLUOROTHYMIDINE F 18;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GRAFT; CONTROLLED STUDY; DISTRIBUTION VOLUME; DRUG TRANSPORT; KINETICS; LEWIS CARCINOMA; MALE; MOUSE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; REPRODUCIBILITY; SQUAMOUS CELL CARCINOMA; STATISTICAL PARAMETERS; STATISTICAL SIGNIFICANCE; TUMOR MODEL;

ANIMALS; CARCINOMA, LEWIS LUNG; CARCINOMA, SQUAMOUS CELL; CELL LINE, TUMOR; DIDEOXYNUCLEOSIDES; DISEASE MODELS, ANIMAL; HUMANS; KINETICS; MALE; MICE; OBSERVER VARIATION; POSITRON-EMISSION TOMOGRAPHY; REPRODUCIBILITY OF RESULTS;

EID: 69249209686     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.nucmedbio.2009.06.001     Document Type: Article

References (35)

1. Therasse P., Arbuck S.G., Eisenhauer E.A., Wanders J., Kaplan R.S., Rubinstein L., et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst 92 (2000) 205-216
2. Twombly R. Criticism of tumor response criteria raises trial design questions. J Natl Cancer Inst 98 (2006) 232-234
3. Goffin J., Baral S., Tu D., Nomikos D., and Seymour L. Objective responses in patients with malignant melanoma or renal cell cancer in clinical studies do not predict regulatory approval. Clin Cancer Res 11 (2005) 5928-5934
4. Canellos G.P. Residual mass in lymphoma may not be residual disease. J Clin Oncol 6 (1988) 931-933
5. Colozza M., Azambuja E., Cardoso F., Sotiriou C., Larsimont D., and Piccart M.J. Proliferative markers as prognostic and predictive tools in early breast cancer: where are we now?. Ann Oncol 16 (2005) 1723-1739
6. Shields A.F., Grierson J.R., Dohmen B.M., Machulla H.J., Stayanoff J.C., Lawhorn-Crews J.M., et al. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography. Nat Med 4 (1998) 1334-1336
7. 18F]fluorothymidine as a new marker for monitoring tumor response to antiproliferative therapy in vivo with positron emission tomography. Cancer Res 63 (2003) 3791-3798
8. Oyama N., Ponde D.E., Dence C., Kim J., Tai Y.C., and Welch M. Monitoring of therapy in androgen-dependent prostate tumor model by measuring tumor proliferation. J Nucl Med 45 (2004) 519-525
9. 18F-fluorothymidine PET. J Nucl Med 46 (2005) 114-120
10. 18F]-fluorothymidine positron emission tomography: the effect of cisplatin on a fibrosarcoma tumor model in vivo. Cancer Res 65 (2005) 4202-4210
11. Pio B.S., Park C.K., Pietras R., Hsueh W.A., Satyamurthy N., Pegram M.D., et al. Usefulness of 3′-[F-18]fluoro-3′-deoxythymidine with positron emission tomography in predicting breast cancer response to therapy. Mol Imaging Biol 8 (2006) 36-42
12. 18F]3′-deoxy-3′-fluorothymidine for prediction of response to neoadjuvant treatment in patients with rectal cancer. Eur J Nucl Med Mol Imaging 34 (2007) 878-883
13. 18F]-fluorothymidine positron emission tomography. Eur J Nucl Med Mol Imaging 34 (2007) 1339-1347
14. 18F]FLT. Eur J Nucl Med Mol Imaging 34 (2007) 1775-1782
15. 18F]-fluorothymidine positron emission tomography in high-grade non-Hodgkin's lymphoma. Clin Cancer Res 13 (2007) 3552-3558
16. 18F]FLT uptake after chemotherapy: an experimental study. Eur J Nucl Med Mol Imaging 29 (2002) 1462-1469
17. Perumal M., Pillai R.G., Barthel H., Leyton J., Latigo J.R., and Forster M. Redistribution of nucleoside transporters to the cell membrane provides a novel approach for imaging thymidine synthase inhibition by positron emission tomography. Cancer Res 66 (2006) 8558-8564
18. 18F-flurodeoxyglucose?. Eur J Nucl Med Mol Imaging 33 (2006) S38-S43
19. Muzi M., Mankoff D.A., Grierson J.R., Wells J.M., Vesselle H., and Krohn K.A. Kinetic modeling of 3′-deoxy-3′-fluorothymidine in somatic tumors: mathematical studies. J Nucl Med 46 (2005) 371-380
20. Muzi M., Vesselle H., Grierson J.R., Mankoff D.A., Schmidt R.A., Peterson L., et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine PET studies: validation studies in patients with lung cancer. J Nucl Med 46 (2005) 274-282
21. 18FLT utilization in colorectal cancer. Eur J Nucl Med Mol Imaging 31 (2004) 169-178
22. 18F]3′-deoxy-3′-fluorothymidine metabolism and retention. Eur J Nucl Med Mol Imaging 32 (2005) 1269-1275
23. 18F-fluorothymidine (FLT) for quantitative cell proliferation imaging in subcutaneous mouse tumor models. J Nucl Med 49 (2008) 2057-2066
24. 18F]fluorothymidine-positron emission tomography imaging: evaluation of analytical methods. Cancer Res 65 (2005) 10104-10112
25. Kelloff G.J., Krohn K.A., Larson S.M., Weissleder R., Mankoff D.A., Hoffman J.M., et al. The progress and promise of molecular imaging probes in oncologic drug development. Clin Cancer Res 11 (2005) 7967-7985
26. 18F-fluorothymidine microPET studies in tumor xenografts in mice. J Nucl Med 46 (2005) 1851-1857
27. 18F]fluorothymidine using nucleophilic fluorination catalyzed by protic solvent. Eur J Nucl Med Mol Imaging 34 (2007) 1406-1409
28. Kim J.S., Lee J.S., Im K.C., Kim S.J., Kim S.Y., Lee D.S., et al. Performance measurement of the microPET focus 120 scanner. J Nucl Med 48 (2007) 1527-1535
29. 18F-FDG microPET studies in mouse tumor xenografts. J Nucl Med 48 (2007) 602-607
30. Minn H., Zasady K.R., Quint L.E., and Wahl R.L. Lung cancer: reproducibility of quantitative measurements for evaluating 2-[F-18]-fluoro-2-deoxy-d-glucose uptake at PET. Radiology 196 (1995) 167-173
31. Weber W.A., Ziegler S.I., Thödtmann R., Hanauske A.R., and Schwaiger M. Reproducibility of metabolic measurements in malignant tumors using FDG PET. J Nucl Med 40 (1999) 1771-1777
32. Muzi M., Spence A.M., O'Sullivan F., Mankoff D.A., Wells J.M., Grierson J.R., et al. Kinetic analysis of 3′-deoxy-3′-fluorothymidine in patients with gliomas. J Nucl Med 47 (2006) 1612-1621
33. 18F-Fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging 34 (2007) 1003-1011
34. Grierson J.R., Shwartz J.L., Muzi M., Jordan R., and Krohn K.A. Metabolism of 3′-deoxy-3′-[F-18]fluorothymidine in proliferating A549 cells: validations for positron emission tomography. Nucl Med Biol 31 (2004) 829-837
35. Taschereau R., and Chatziioannou A.F. Monte Carlo simulations of absorbed dose in a mouse phantom from 18-flurine compounds. Med Phys 34 (2007) 1026-1036